Abstract
Background: In December 2019, China announced the first case of an infection caused by an, until then, unknown virus: SARS-CoV-2. Since then, researchers have been looking for viable alternatives for the treatment and/or cure of viral infection. Among the possible complementary solutions are lectins, proteins that are reversibly bound to different carbohydrates. The Spike protein, present on the viral surface, can interact with different cell receptors: ACE2, CD147, and DC-SIGNR. Since lectins have an affinity for different carbohydrates, the binding with the glycosylated cell receptors represents a possibility of preventing the virus from binding to the receptors of host cells.
Objective: In this review, we discuss the main lectins that are possible candidates for use in the treatment of Covid-19, highlighting those that have already demonstrated antiviral activity in vivo and in vitro, including mannose-binding lectin, Griffithsin, BanLec, and others. We also aim to discuss the possible mechanism of action of lectins, which appears to occur through the mediation of viral fusion in host cells, by binding of lectins to glycosylated receptors found in human cells and/or binding of these proteins with the spike glycoprotein, present in virus surface. Moreover, we discuss the use of lectins in clinical practice.
Conclusion: Even with the development of effective vaccines, new cases of viral infection with the same virus, or new outbreaks with different viruses can occur; so, the development of new treatments should not be discarded. Moreover, the discussions made in this work are relevant regarding the anti-viral properties of lectins.
Keywords: Virus inhibition, agglutinins, capsid glycoprotein, covid-19, spike protein, antiviral activity, antiviral proteins.
Current Pharmaceutical Design
Title:The Use of Lectins as Tools to Combat SARS-CoV-2
Volume: 27 Issue: 41
Author(s): Daniela Martinez, Diego Amaral, David Markovitz and Luciano Pinto*
Affiliation:
- Laboratory of Bioinformatics and Proteomics, Technological Development Center, Federal University of Pelotas, Capao do Leao, Rio Grande do Sul,Brazil
Keywords: Virus inhibition, agglutinins, capsid glycoprotein, covid-19, spike protein, antiviral activity, antiviral proteins.
Abstract:
Background: In December 2019, China announced the first case of an infection caused by an, until then, unknown virus: SARS-CoV-2. Since then, researchers have been looking for viable alternatives for the treatment and/or cure of viral infection. Among the possible complementary solutions are lectins, proteins that are reversibly bound to different carbohydrates. The Spike protein, present on the viral surface, can interact with different cell receptors: ACE2, CD147, and DC-SIGNR. Since lectins have an affinity for different carbohydrates, the binding with the glycosylated cell receptors represents a possibility of preventing the virus from binding to the receptors of host cells.
Objective: In this review, we discuss the main lectins that are possible candidates for use in the treatment of Covid-19, highlighting those that have already demonstrated antiviral activity in vivo and in vitro, including mannose-binding lectin, Griffithsin, BanLec, and others. We also aim to discuss the possible mechanism of action of lectins, which appears to occur through the mediation of viral fusion in host cells, by binding of lectins to glycosylated receptors found in human cells and/or binding of these proteins with the spike glycoprotein, present in virus surface. Moreover, we discuss the use of lectins in clinical practice.
Conclusion: Even with the development of effective vaccines, new cases of viral infection with the same virus, or new outbreaks with different viruses can occur; so, the development of new treatments should not be discarded. Moreover, the discussions made in this work are relevant regarding the anti-viral properties of lectins.
Export Options
About this article
Cite this article as:
Martinez Daniela , Amaral Diego , Markovitz David and Pinto Luciano *, The Use of Lectins as Tools to Combat SARS-CoV-2, Current Pharmaceutical Design 2021; 27 (41) . https://dx.doi.org/10.2174/1381612827666210830094743
DOI https://dx.doi.org/10.2174/1381612827666210830094743 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
GLP-1 Receptor Agonists and Type 1 Diabetes - Where Do We Stand?
Current Pharmaceutical Design Wnt Signaling and Potential Applications in Bone Diseases
Current Drug Targets Abnormalities of Peptide Metabolism in Alzheimer Disease
Current Neurovascular Research Antihyperlipidemic and Antiobesity Potential of <i>Aquilaria agallocha</i> and <i>Borago officinalis</i> in Fixed-Dose Combination; A Contingent Probe with Atorvastatin and Orlistat
Current Bioactive Compounds Pharmacological Modulation of Th17
Recent Patents on Inflammation & Allergy Drug Discovery Brain Stimulation in Obsessive-Compulsive Disorder (OCD): A Systematic Review
Current Neuropharmacology Bioproducts from Seaweeds: A Review with Special Focus on the Iberian Peninsula
Current Organic Chemistry Cardiovascular Complications in Patients with Turner’s Syndrome
Current Pharmaceutical Design Lipid Nanocarriers and Molecular Targets for Malaria Chemotherapy
Current Drug Targets Regulation of B Cell Activation by PECAM-1: Implications for the Development of Autoimmune Disorders
Current Pharmaceutical Design Perspectives on the Tertiary Prevention Strategy for Alzheimer’s Disease
Current Alzheimer Research Cytosine Methyltransferases as Tumor Markers
Current Genomics Novel Systemic Drugs for Cutaneous T-Cell Lymphoma
Recent Patents on Anti-Cancer Drug Discovery How to Make a Non-Antigenic Protein (Auto) Antigenic: Molecular Complementarity Alters Antigen Processing and Activates Adaptive-Innate Immunity Synergy
Anti-Cancer Agents in Medicinal Chemistry Some clinical applications of the electrochemical biosensors
Mini-Reviews in Medicinal Chemistry An Increasing Incidence of Treatment Resistance in Hypertension?
Current Drug Therapy Phytochemical-Mediated Glioma Targeted Treatment: Drug Resistance and Novel Delivery Systems
Current Medicinal Chemistry Pathology and Development - Developmental Systems for Target Validation and Drug Screening in Osteoarthritis
Drug Design Reviews - Online (Discontinued) Th17 and Treg Cells, Two New Lymphocyte Subpopulations with a Key Role in the Immune Response Against Infection
Infectious Disorders - Drug Targets Small Molecule Antagonists of the Chemokine Receptor CCR5
Current Topics in Medicinal Chemistry